ArticleObesity science & practice2016
Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction-induced weight loss in rats.
Article in Obesity science & practice, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Serum Preptin and Amylin Levels with Respect to Body Mass Index in Polycystic Ovary Syndrome Patients.Medical science monitor : international medical journal of experimental and clinical research · 2018Trial
- Altered serum amylin and preptin levels in women with polycystic ovary syndrome: a comparative analysis based on obesity status.Journal of endocrinological investigation · 2026Article
- Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions.Endocrinology, diabetes & metabolism · 2026Review
- Management of Obese Patients with Cardiovascular Disease with Emerging Weight-Lowering Drugs: A Narrative Review.Biomedicines · 2026Review
- The story of amylin: from physiology to therapy.Nature metabolism · 2026Review
- Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity.Journal of obesity & metabolic syndrome · 2026Review
- Hormonal predictors of the lean phenotype in humans.Biomolecules & biomedicine · 2025Article
- The role of amylin, a gut-brain axis hormone, in metabolic and neurological disorders.FASEB bioAdvances · 2025Review
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity.International journal of molecular sciences · 2024Review
- Factors of Obesity and Metabolically Healthy Obesity in Asia.Medicina (Kaunas, Lithuania) · 2022Review
- Mediators of Amylin Action in Metabolic Control.Journal of clinical medicine · 2022Review
- Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?Lipids in health and disease · 2020Review
- Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.Nature reviews. Endocrinology · 2019Review
- Leptin and Leptin Resistance in the Pathogenesis of Obstructive Sleep Apnea: A Possible Link to Oxidative Stress and Cardiovascular Complications.Oxidative medicine and cellular longevity · 2018Review
- Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction-induced weight loss in rats.Obesity science & practice · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCo-administration of amylin and leptin induces synergistic and clinically meaningful (>10%) weight loss that is attenuated as the degree of obesity increases. We explored whether calorie restriction (CR) could restore amylin/leptin synergy in very obese rats.
methodsSprague Dawley rats on high-fat diet (696 ± 8 g,
resultsIn C1, leptin did not alter weight, and amylin induced 40.2 ± 6.1 g weight loss (-6.0 ± 0.9%), which was not enhanced by leptin (44.4 ± 4.9 g, -6.1 ± 0.8%). In C2, vehicle-treated (75.1 ± 7.8 g weight change from start of treatment, 1.1 ± 0.8% difference from start of pre-CR phase) and leptin-treated rats (68.6 ± 9.2 g, -1.3 ± 1.0%) rebounded to pre-restriction weight that was attenuated by amylin (29.2 ± 11.4 g, -6.2 ± 0.7%). Leptin did not enhance the effect of amylin (22.8 ± 11.7 g, -8.3 ± 1.5%). In C3, vehicle-treated and leptin-treated rats regained most of their weight (161.9 ± 11.8, -2.3 ± 0.8% and 144.6 ± 9.5 g, -2.3 ± 0.9%, respectively), which was attenuated by amylin (91.1 ± 16.8 g, -11.2 ± 0.7%), but not enhanced by leptin (83.0 ± 7.6 g, -10.7 ± 0.8%).
conclusionsExtreme obesity associated with leptin resistance perturbs amylin/leptin weight loss synergy in rats, which cannot be restored by pre-treatment weight loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.